Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, Cazzaniga G, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A. Magnani CF, et al. Among authors: ferrari s. J Clin Invest. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473. J Clin Invest. 2020. PMID: 32780725 Free PMC article. Clinical Trial.
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL.
Gritti G, Ferrari S, Lussana F, Barbui AM, Landi F, Rondi M, Putelli A, Ballardini F, Quaresmini G, Paganessi M, Pavoni C, Ghirardi A, Gotti E, Capelli C, Golay J, Introna M, Rambaldi A. Gritti G, et al. Among authors: ferrari s. Blood Cancer J. 2024 Apr 26;14(1):73. doi: 10.1038/s41408-024-01057-z. Blood Cancer J. 2024. PMID: 38670983 Free PMC article.
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Gotti M, Sciarra R, Pulsoni A, Merli F, Luminari S, Zerbi C, Trentin L, Re A, Rusconi C, Viviani S, Rossi A, Cocito F, Botto B, Meli E, Pinto A, Dogliotti I, Gini G, Puccini B, Ricci F, Nassi L, Fabbri A, Liberati AM, Merli M, Filippi AR, Bonfichi M, Zoboli V, Tartaglia G, Annechini G, D'Elia GM, Del Giudice I, Alvarez I, Visentin A, Pravato S, Dalceggio D, Pagani C, Ferrari S, Cristinelli C, Lazic T, Ferretti VV, Ricardi U, Arcaini L. Gotti M, et al. Among authors: ferrari s. Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37034003 Free PMC article.
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.
Scarfò L, Ferrari S, Frustaci AM, Tani M, Bari A, Scarano E, Colia M, Ranghetti P, Angelillo P, Ronchi P, Ponzoni M, Ferreri AJM, Ghia P. Scarfò L, et al. Among authors: ferrari s. Blood Adv. 2022 Sep 27;6(18):5356-5359. doi: 10.1182/bloodadvances.2022007138. Blood Adv. 2022. PMID: 35613463 Free PMC article. Clinical Trial. No abstract available.
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA 3rd, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau FI, Radford J, de Oteyza JP, Zinzani PL, Iyer SP, Townsend W, Miao H, Proscurshim I, Wang S, Katyayan S, Yuan Y, Zhu J, Stumpo K, Shou Y, Carpio C, Bosch F. Gordon LI, et al. Among authors: ferrari s. Oncotarget. 2023 Jan 26;14:57-70. doi: 10.18632/oncotarget.28352. Oncotarget. 2023. PMID: 36702329 Free PMC article. Clinical Trial.
2,630 results